Prostate cancer in a transgender woman 41 years after initiation of feminization [9]

JAMA

Volumn 296, Issue 19, 2006, Pages 2316-2317

  Miksad, Rebecca A ^a   Bubley, Glenn ^a   Church, Paul ^a   Sanda, Martin ^a   Rofsky, Neil ^a   Kaplan, Irving ^a   Cooper, Amiel ^b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b Brigham and Women's/Faulkner Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANTIANDROGEN; BICALUTAMIDE; DUTASTERIDE; ESTROGEN; PROGESTERONE RECEPTOR; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; ANAMNESIS; CANCER RADIOTHERAPY; CANCER SIZE; CASE REPORT; CELL INFILTRATION; DOSE RESPONSE; FEMINIZATION; GLEASON SCORE; HEMATURIA; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LETTER; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE TUMOR; PROTEIN EXPRESSION; RECTUM BIOPSY; TRANSRECTAL ULTRASONOGRAPHY; VAGINAL CYST;

EID: 33750982363     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.296.19.2316     Document Type: Letter

References (8)

1. van Haarst EP, Newling DW, Gooren LJ, Asscheman H, Prenger DM. Metastatic prostatic carcinoma in a male-to-female transsexual. Br J Urol. 1998;81:776.
2. Thurston AV. Carcinoma of the prostate in a transsexual. Br J Urol. 1994;73:217.
3. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA. 2005;294:238-244.
4. Wilson JD, Roehrborn C. Long-term consequences of castration in men: lessons from the Skoptzy and the eunuchs of the Chinese and Ottoman courts. J Clin Endocrinol Metab. 1999;84:4324-4331.
5. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol. 2005;23:8253-8261.
6. van Kesteren P, Meinhardt W, van der Valk P, Geldof A, Megens J, Gooren L. Effects of estrogens only on the prostates of aging men. J Urol. 1996;156:1349-1353.
7. Latil A, Bieche I, Vidaud D, et al. Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. Cancer Res. 2001;61:1919-1926.
8. Tsukamoto S, Akaza H, Onozawa M, Shirai T, Ideyama Y. A five-alpha reductase inhibitor or an anti-androgen prevents the progression of microscopic prostate carcinoma to macroscopic carcinoma in rats. Cancer. 1998;82:531-537.